{"analyses":[{"ciLowerLimit":"0.819","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.517","groupDescription":"The analysis was stratified for 1) World region (United States, Western Europe, or Other); 2) Number of prior regimens, excluding single-agent hormones, for treatment of metastatic or unresectable locally advanced/recurrent disease (≤ 3 or \\> 3); and 3) Presence of visceral disease (any visceral disease vs no visceral disease).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4952","paramType":"Hazard Ratio (HR)","paramValue":"1.115","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"3.7","value":"2.9"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"4.5","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"description":"Time to pain symptom progression was defined as the time from randomization to the first documentation of an increase in narcotic use and/or a 10 point increase from Baseline in the pain score as measured by the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire for patients with bone metastases (EORTC QLQ-BM22). The EORTC QLQ-BM22 assesses the symptoms of bone metastases using 22 items: 5 items for sites of pain, 3 pain characteristics, 8 functional interference aspects, and 6 psychosocial aspects. The pain score was derived from the 3 pain characteristic items. Each item was rated on a 4-point scale, where 1=Not at all to 4=Very much. The pain score was the sum of the 3 pain characteristic scores and was normalized to a scale of 0 to 100. A higher score indicates greater pain.","dispersionType":"95% Confidence Interval","groups":[{"description":"Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.","id":"OG001","title":"Treatment of Physician's Choice"}],"paramType":"MEDIAN","populationDescription":"Randomized population: All participants who were randomized to the study. Only participants with a Baseline pain score and at least 1 post-baseline pain score were included in the analysis. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)","title":"Time to Pain Symptom Progression","type":"SECONDARY","unitOfMeasure":"Months"}